# Luteolin

> Luteolin is a plant flavonoid (celery, parsley, artichokes) that stabilizes mast cells more potently than prescription cromolyn sodium in lab studies and crosses the blood-brain barrier to address neuroinflammation. The EDS UK GP Toolkit lists it as an option to consider for MCAS management in hEDS patients. ZebraThrive uses 140 mg daily of a micronized form in the Daily Powder.

**Page:** https://www.wellnessforzebras.com/ingredients/luteolin
**Brand:** ZebraThrive
**Author:** Ken Chapman, Founder of ZebraThrive
**Last reviewed:** 2026-05-11
**Daily dose:** 140 mg daily in the Daily Powder, split AM and PM scoops (per v7.8 RFQ)
**Form used:** Generic micronized luteolin (≤25 μm particle size, COA-verified)
**Target population:** Adults 18+ with hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), or Mast Cell Activation Syndrome (MCAS).
**Regulatory framing:** US DSHEA dietary supplement. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

## Key benefits

- Superior to cromolyn sodium at inhibiting histamine, tryptase, and inflammatory cytokines
- Crosses the blood-brain barrier to reduce neuroinflammation
- Listed by the EDS UK GP Toolkit as an option to consider for MCAS management
- Minimal drug interactions with common POTS/MCAS medications

## What it is

A plant flavonoid (celery, parsley, artichokes) that stabilizes mast cells more potently than prescription cromolyn sodium in head-to-head lab studies

## Why we include it

Luteolin stabilizes mast cells more potently than prescription cromolyn sodium in head-to-head lab studies, with excellent safety and minimal drug interactions

## Plain-language summary

Luteolin is a plant compound found in celery, parsley, artichokes, and chamomile - and it happens to be one of the most studied natural mast cell stabilizers in the world. For people with MCAS, it calms the cells that misfire and release histamine, tryptase, and inflammatory chemicals into your body. In head-to-head lab tests, luteolin actually outperformed cromolyn - blocking a wider range of inflammatory signals like IL-6, IL-8, and TNF. For hEDS and POTS, mast cell calm tends to ripple outward: fewer flares, less brain fog, steadier autonomic function. We use a micronized form because standard luteolin barely absorbs.

## Mechanism

Think of luteolin as a master mast cell controller that works through multiple locks simultaneously. While cromolyn sodium (Gastrocrom) works through one pathway, luteolin blocks mast cell activation through several.

First, luteolin prevents calcium from entering mast cells-calcium influx is the trigger for degranulation. No calcium surge, no histamine release. Second, it blocks NF-κB, a master switch for inflammatory gene expression. Third, it inhibits protein kinase C (PKC), another pathway that leads to mast cell activation.

What makes luteolin special is that it's the most lipophilic (fat-loving) flavonoid, meaning it crosses the blood-brain barrier effectively. This matters because many patients experience "brain fog" and cognitive symptoms-luteolin can reduce neuroinflammation directly in the brain where it's causing problems. It also induces synthesis of brain-derived neurotrophic factor (BDNF) and other compounds that support nerve health.

## Condition-specific notes

### MCAS (Mast Cell Activation Syndrome)

Luteolin represents one of the most effective natural mast cell stabilizers available. Research demonstrates it inhibits not just histamine, but also tryptase, IL-6, IL-8, TNF-α, and other mediators-providing broader coverage than cromolyn which primarily targets histamine. Importantly, luteolin works prophylactically (preventively). The EDS UK GP Toolkit (Royal College of General Practitioners) lists luteolin as an option to consider for MCAS management.

### hEDS (hypermobile Ehlers-Danlos Syndrome)

Luteolin provides indirect benefit to hEDS patients through anti-inflammatory effects and MCAS management (14-47% of hEDS patients have comorbid MCAS). However, luteolin does NOT achieve sufficient plasma concentrations to inhibit MMPs-don't expect direct collagen-protective effects. Its value for hEDS is through mast cell stabilization and inflammation reduction, not ECM protection.

### POTS (Postural Orthostatic Tachycardia Syndrome)

Luteolin's ability to cross the blood-brain barrier makes it uniquely valuable for POTS patients experiencing brain fog, cognitive dysfunction, and neurological symptoms. It reduces microglial activation and central neuroinflammation. Additionally, it stabilizes mast cells around autonomic nerve fibers and may support vagal tone by reducing inflammatory interference with the autonomic nervous system.

## Why this form

**Selected form:** Generic micronized luteolin (≤25 μm particle size, COA-verified)

Standard luteolin powder has poor bioavailability; only 4-17% reaches the bloodstream, so plasma levels after standard doses are often undetectable. The fix is particle size reduction. We use generic micronized luteolin verified by Certificate of Analysis (≤25 μm spec, the threshold the clinical trial forms used). Liposomal and PEA-luteolin co-ultramicronized forms are valid alternatives with their own evidence but are not what we ship; we co-formulate PEA and luteolin separately in the Daily Powder.

**Form comparison:**

| Form | Notes | Selected |
|---|---|---|
| Standard luteolin powder | Only 4-17% bioavailability; most passes through unabsorbed | No |
| Generic micronized luteolin (≤25 μm, COA-verified) | Reduced particle size improves absorption to clinical-trial range | Yes |
| Liposomal luteolin | Alternative carrier technology with 2-3x improved absorption; not used here | No |
| Co-ultramicronized PEA-luteolin (10:1 ratio) | Co-processed branded combo; we deliver both separately in the powder | No |

## Dose protocol

| Step | Dosage | Notes |
|---|---|---|
| Week 1 | 50 mg once daily | Take with fatty meal |
| Week 2 | 50 mg twice daily | Morning and evening with meals |
| Week 3 | 70 mg once daily | Increase single dose |
| Week 4+ | 70 mg twice daily | Target maintenance dose |

**Timeline to effect:** Allow 4-6 weeks for full therapeutic effect. Many patients report initial improvement around week 3-4. Consistent daily dosing is important due to the short half-life.

## Evidence summary

### Superior Mast Cell Stabilization

Head-to-head comparisons show luteolin outperforms the prescription mast cell stabilizer cromolyn sodium.

- [1] **Tsilioni I & Theoharides TC, "Luteolin more effective than cromolyn at inhibiting mast cell activation".** Design: Cultured human mast cell comparison study. Finding: Luteolin more effectively inhibited release of histamine, tryptase, IL-6, IL-8, and TNF-α across 10 different inflammatory markers compared to cromolyn. PMID: 38588651.

### Neuroinflammation and Brain Fog

Luteolin's ability to cross the blood-brain barrier provides unique benefits for cognitive symptoms.

- [2] **Theoharides TC et al., "Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue".** Design: Review of luteolin mechanisms in neuroinflammation. Finding: Luteolin reduces microglial activation and IL-6 production in the brain, directly addressing mechanisms underlying brain fog. PMID: 33847020.

### Clinical Trial Evidence

While no direct MCAS trials exist, clinical studies using luteolin show meaningful effects.

- [3] **Di Stadio A et al., "Ultramicronized PEA and Luteolin Supplement Combined with Olfactory Training".** Design: Clinical trial in post-COVID patients. Finding: Significant improvements in inflammatory markers and symptoms over 4-6 months using PEA-luteolin combination. PMID: 35086448.

## Evidence gaps

No randomized controlled trials exist specifically in MCAS, hEDS, or POTS populations. Evidence for superior mast cell stabilization comes from in vitro studies comparing luteolin to cromolyn. However, the EDS UK GP Toolkit (Royal College of General Practitioners) lists luteolin as an option to consider for MCAS management in hEDS patients. Additionally, luteolin CANNOT achieve MMP inhibition at oral doses-its value lies exclusively in mast cell stabilization, not collagen protection.

## Safety

**Side effects:** Luteolin demonstrates an excellent safety profile in clinical trials up to 26 weeks. Very few adverse effects are reported even in highly reactive MCAS individuals. Unlike quercetin, which causes paradoxical reactions in 10-15% of MCAS patients, luteolin is generally well-tolerated.

**Interactions:** Luteolin shows minimal CYP450 enzyme interactions. No direct interactions found with beta blockers, antihistamines, fludrocortisone, midodrine, or cromolyn/ketotifen. Theoretical caution with anticoagulants (may enhance effects).

**Cautions:** Not recommended during pregnancy or breastfeeding pending more human safety data. Discontinue 2 weeks before surgery. Iron supplements may reduce absorption; space by 2+ hours. Allow 4-6 weeks for full therapeutic effect.

**Excipients to avoid:** Microcrystalline cellulose (wood-derived), Magnesium stearate, FD&C dyes, Sodium lauryl sulfate

**Excipients that are safe:** Sunflower lecithin, Olive pomace oil, Rice flour

## Frequently asked questions

### What does luteolin do that quercetin doesn't?

Both stabilize mast cells, but luteolin has two real edges. It crosses the blood-brain barrier better - important when you're fighting MCAS brain fog or neuroinflammation. And it skips the ivabradine interaction concern that quercetin carries. In direct head-to-head testing against cromolyn, luteolin blocked a wider range of inflammatory chemicals - including the cytokines (IL-1β, IL-6, TNF) that cromolyn doesn't affect. For a single mast cell calmer with the broadest reach, luteolin is a strong pick.

### Why does luteolin need a special form?

Standard luteolin powder barely dissolves in water. The clinical-trial forms use micronization, particles ground to single-digit microns so the gut can actually absorb them, and that's the spec we use. Cheap retail luteolin tablets typically aren't micronized, which is one reason their results disappoint.

### How should I start luteolin if I'm reactive?

Start low and go slow. A subset of MCAS patients are reactive to anything that touches their mast cells in the early days - the same is true for cromolyn, ketotifen, and luteolin. The standard approach is to start at a fraction of the target dose and step up over 2-3 weeks. This gives your system time to adjust to the calmer baseline. Most people tolerate the full dose just fine once they've ramped up.

### How long until I notice anything?

Mast cell stabilizers don't work like antihistamines - they make flares harder to trigger in the first place. Most people who respond start noticing the difference in 4-8 weeks of consistent dosing, and trials that have shown meaningful benefit typically ran 2-6 months. Daily consistency is what unlocks the benefit. Build it into your routine the same way you would any prescription, and the effects build steadily over the first couple of months.

## References

[1] Tsilioni I & Theoharides TC. (2024). Luteolin more effective than cromolyn sodium at inhibiting mast cell activation. PMID: 38588651. https://pubmed.ncbi.nlm.nih.gov/38588651/
[2] Theoharides TC et al.. (2021). Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescue. PMID: 33847020. https://pubmed.ncbi.nlm.nih.gov/33847020/
[3] Di Stadio A et al.. (2022). Ultramicronized PEA and Luteolin Supplement Combined with Olfactory Training. PMID: 35086448. https://pubmed.ncbi.nlm.nih.gov/35086448/
[4] Bertolino B et al.. (2017). Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism. PMID: 27611916. https://pubmed.ncbi.nlm.nih.gov/27611916/